Ryan Fukushima

Tempus AI, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Tempus AI, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Tempus AI, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Tempus AI, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Tempus AI, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

The American company was founded by Ryan Fukushima and Eric Paul Lefkofsky, with Ryan Fukushima serving as the CEO since incorporation. Pathos AI leverages the power of AI technologies, multimodal real-world data, and patient-derived biological models to bring precision medicines to market through partnerships with biopharmaceutical companies. The company is focused on re-engineering drug development with the power of advanced AI technologies and has built a proprietary platform and operating model called Pathos to gain crucial insights and act on them at scale.

Hyde Park Venture Partners Management LLC (Hyde Park Venture Partners) is a venture capital firm founded in 2011 by Guy Turner. The firm is headquartered in Chicago, Illinois.

Tempus AI, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Tempus AI, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

The American company was founded by Ryan Fukushima and Eric Paul Lefkofsky, with Ryan Fukushima serving as the CEO since incorporation. Pathos AI leverages the power of AI technologies, multimodal real-world data, and patient-derived biological models to bring precision medicines to market through partnerships with biopharmaceutical companies. The company is focused on re-engineering drug development with the power of advanced AI technologies and has built a proprietary platform and operating model called Pathos to gain crucial insights and act on them at scale.

Lightbank LLC (Lightbank) is a venture capital firm founded in 2010 by Eric Paul Lefkofsky and Bradley A. Keywell. The firm is headquartered in Chicago, Illinois.